Greenwich LifeSciences, Inc.
No enriched coverage for $GLSI in the last 7 days.
Investing.com reported Thursday’s US insider trading roundup. Conagra CEO John Brase bought 35,000 shares for $510,632, and Albertsons CEO Susan Morris bought 39,409 shares for $449,937. CoreWeave CEO Michael Intrator sold about $20.5M, Charles Schwab co-chairman Charles Schwab sold about $15.17M, and Snowflake director Benoit Dageville sold $14M, mostly under 10b5-1 plans.
Greenwich LifeSciences (NASDAQ:GLSI) CEO/CFO Snehal Patel bought $29,555 of GLSI common stock on July 28-29, 2026, acquiring 2,200 shares at $13.10 to $13.59. Patel is also a director and 10% owner. The stock is down 57% in six months to about $12.80. The company also updated its Phase III FLAMINGO-01 trial after FDA/EMA review.
Patel Snehal (CEO and CFO) purchased 2,200 shares of Greenwich LifeSciences, Inc. (GLSI) at an average of $13.43 ($13.10–$13.59) across 2 trades over 2026-07-28 to 2026-07-29.
Recent GLSI coverage spans technology, insider activity and regulation.
In the last 30 days, GLSI insiders filed 5 SEC Form 4 transactions — 5 purchases ($97K) and no sales. The most active reporter was Patel Snehal, CEO and CFO, with 5 filings.
Insider buying after a steep drop may attract speculative interest, but the dollar amount is relatively small.
Insider buying is a modest bullish signal, but the article’s main tradable catalyst is the disclosed Phase III protocol and manufacturing approvals.
This is a routine insider open-market purchase with modest dollar size, offering limited incremental signal on near-term fundamentals.
Insider open-market buying by the CEO/CFO can modestly support sentiment, but it is not a fundamental catalyst by itself.
Insider open-market buying by the CEO/CFO is a modest positive signal, but it is not a fundamental catalyst like earnings or guidance.
alphai scores every news story that mentions GLSI with an AI model for sentiment and relevance, and aggregates insider trades from Greenwich LifeSciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Investing.com reported Thursday’s US insider trading roundup. Conagra CEO John Brase bought 35,000 shares for $510,632, and Albertsons CEO Susan Morris bought 39,409 shares for $449,937. CoreWeave CEO Michael Intrator sold about $20.5M, Charles Schwab co-chairman Charles Schwab sold about $15.17M, and Snowflake director Benoit Dageville sold $14M, mostly under 10b5-1 plans.
7 min readGreenwich LifeSciences (NASDAQ:GLSI) CEO/CFO Snehal Patel bought $29,555 of GLSI common stock on July 28-29, 2026, acquiring 2,200 shares at $13.10 to $13.59. Patel is also a director and 10% owner. The stock is down 57% in six months to about $12.80. The company also updated its Phase III FLAMINGO-01 trial after FDA/EMA review.
3 min readPatel Snehal (CEO and CFO) purchased 2,200 shares of Greenwich LifeSciences, Inc. (GLSI) at an average of $13.43 ($13.10–$13.59) across 2 trades over 2026-07-28 to 2026-07-29.
3 min readPatel Snehal (CEO and CFO) purchased 1,500 shares of Greenwich LifeSciences, Inc. (GLSI) at $13.62 on 2026-07-27.
2 min readPatel Snehal (CEO and CFO) purchased 3,600 shares of Greenwich LifeSciences, Inc. (GLSI) at an average of $13.06 ($12.88–$13.14) across 2 trades over 2026-07-23 to 2026-07-24.
2 min readGreenwich LifeSciences (GLSI) said U.S. and European regulators approved changes to its FLAMINGO-01 Phase III trial of GLSI-100 for breast cancer recurrence. The DSMB recommended continuing without changes. Enrollment now includes non-HLA-A*02 patients, expected to more than double enrollment rate. In a 250-patient arm, preliminary results show a 70-80% recurrence reduction. Cash was about $8.9M at June 30, 2026.
5 min readGreenwich LifeSciences (GLSI) shares rose 5.4% in pre-open trading after the company published a detailed clinical update on its Phase III FLAMINGO-01 trial. The update said the DSMB met in May 2026 and recommended the study continue without modification, and it outlined trial design changes affecting interim analysis and success probability.
4 min readGreenwich LifeSciences (NASDAQ:GLSI) shares rose 7.7% after the European Medicines Agency approved commercially manufactured GP2 for its FLAMINGO-01 Phase III trial of GLSI-100 to prevent breast cancer recurrence. The approval lets US and Europe sites use the same GP2 lot. The company said sites increased to about 170-180 and shipments to European pharmacies are underway.
4 min readGreenwich LifeSciences (GLSI) said the EMA approved use of its commercially manufactured GP2 immunotherapy in the Phase III FLAMINGO-01 trial for breast cancer recurrence prevention. The company previously made three commercial lots in 2023 and has begun U.S. site use. European sites will now use the same lot; GLSI-100 trial enrollment and screening are ongoing.
3 min readGreenwich LifeSciences (Nasdaq: GLSI) said the EMA has completed review and will allow use of commercially manufactured GP2 in its FLAMINGO-01 Phase III trial of GLSI-100 in Europe. The same GP2 lot was approved for US use in early 2026 and is being used at about 170-180 sites. The company reported preliminary 70-80% recurrence reduction in a non-HLA-A*02 arm after the primary immunization series.
4 min read
